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Objective: To evaluate the capability of recombinant Leishmania LPG3 and its frag-
ments in the activation of B cells.
Methods: In the present study, human B cells were puriﬁed from peripheral blood of 10
adult healthy subjects usingmagnetic-activated cell sorting technique. Subsequently, puriﬁed
B cells were treated with recombinant LPG3, and its N-terminal and C-terminal fragments at
different concentrations (2, 10 and 20 mg/mL). B cell activation was assessed through
expression of CD69 molecule by ﬂow cytometry and secretion of IL-6, TNF-a and IL-10
cytokines via enzyme-linked immunosorbent assay following treatment with recombinant
antigens.
Results: Our results showed that while the recombinant LPG-3 could signiﬁcantly in-
crease the production of IL-6 and TNF-a (P < 0.05) in B cells, it had no effect on the
secretion of IL-10 by B cells.
Conclusions: Our study indicated that recombinant LPG-3 and especially its N-terminal
fragment could stimulate B cell response as an important immune response component
against leishmaniasis. Thus, it seems that it can be considered as an effective adjuvant in
vaccine developments against leishmaniasis.1. Introduction
Leishmaniasis is one of the important infectious diseases
caused by an obligate intracellular parasite. It has been demon-
strated that over 20 genus of Leishmania can induce this disease
and their life cycle alternates between two separate developmental
stages including promastigotes and amastigotes. The promastigote
stage is related to ﬂagellated extracellular stage in which parasite
replicate into midgut of the insect vector, whereas amastigotes is
referred to intracellular stage in which aﬂagellate parasite multiply
within mammalian host macrophages [1,2]. The epidemiologic
studies have been shown that Leishmaniasis is endemic in 88
countries, affecting 12 million people and an estimated 1.5
million to 2 million new cases occur worldwide annually.
Leishmania infection is prevalent in tropical and subtropical
areas of Asia, Africa, southern Europe, the Mediterranean (oldworld) and central and south America (new world).
Leishmaniasis appears in various forms including cutaneous
(the most common), visceral which also known as kala-azar
(the most severe form of the disease) and mucocutaneous [1–3].
The clinical manifestation of disease may various from self-
healing chronic cutaneous lesions to progressive and fatal sys-
temic infection, if left untreated. It has been shown that while the
cutaneous Leishmaniasis is caused by Leishmania aethiopica,
Leishmania tropica and Leishmania major in the old world, it
could be induced by Leishmania braziliensis, Leishmania mex-
icana, Leishmania guyanensis, and Leishmania amazonensis in
the new world. CL is the most common in Pakistan, Saudi Arabia,
Algeria, Syria, Tunisia, Afghanistan and Iran [4,5].
Paromomycin, pentavalent antimonial, amphotericin B and
miltefosine are different chemical drugs used in the control and
treatment of Leishmania [6,7]. However, application of these
drugs was associated with several side effects and drug
resistance which led to their limited prescription.
The several vaccination approaches such as whole killed
parasites (as a ﬁrst generation), poly-proteins, recombinant
proteins or dendritic cells pulsed with Leishmania-derivedaccess article under the CC BY-NC-ND
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generation) have recently been developed, however, none of
them was sufﬁcient to protect humans against infection [8,9].
Lipophosphoglycan (LPG) is a highly expressed surface
molecule on Leishmania promastigotes. Regarding the protective
role of LPG for parasite against phagocytosis, it plays an important
role in parasite's survival [10,11]. Leishmania lipophosphoglycan3
(LPG3) is essential for the synthesis of glycoconjugate
molecules, particularly LPG. Thus, it has been thought that
LPG3 may has a critical role in parasites infectivity [10,11].
In addition to antibody synthesis, B lymphocytes regulate im-
mune responses and participate in inﬂammation via secretion of
cytokines, growth factors, chemokines and also regulate T cell
responses. Several studies showed thatB cells can enhanceTh1 and
Th2 responses [12,13]. HumanB lymphocytes are able to secrete IL-
6 and TNF-a as pro inﬂammatory cytokines [14,15]. Some studies
demonstrated that antibodies secreted by B cells result in killing
of infected macrophages and intracellular parasite [16–18].
In the present study, we evaluated the capability of recom-
binant Leishmania LPG3 and its fragments in the activation of B
cells. We assessed activation of B cells through the production
of IL-6, TNF-a (as pro-inﬂammatory cytokines), and IL-10 (as
an immune-regulatory cytokine) cytokines and expression of
activation CD69 molecule.
2. Material and methods
2.1. B cells isolation by magnetic-activated cell sorting
(MACS)
The heparinized peripheral blood samples were collected
from 10 adult healthy volunteers with no history of Leish-
mania infection after obtaining their informed consent. Pe-
ripheral blood mononuclear cells (PBMCs) were isolated by
density gradient centrifugation on Ficoll–Paque (Sigma, St.
Louis, MO) from whole blood, as described previously [19].
Negative selection (depletion of unwanted cells) were used
to isolate B cells from PBMC (B cell isolation kit II,
Miltenyi Biotech, Bergisch-Gladbach, Germany), according
to the manufacturers instruction. For magnetic labeling,
PBMCs were washed twice with MACS buffer reagent
(300 ×g for 10 min) and supernatant was completely removed.
PBMCs were incubated with 10 mL of B cell biotin-antibodyFigure 1. Histogram graphs of puriﬁed B cells by MACS method.
The isolated cells were stained with FITC-anti-CD19 and isotype control antibcocktail per 107 total cells for 5 min in the refrigerator
(2 C–8 C). Subsequently, the cells were resuspended in
40 mL of MACS buffer per 107 total cells. After incubation,
30 mL of MACS buffer and 20 mL of B cell microbead cocktail
were added per 107 total cells. Cells suspension incubated for
10 min in the refrigerator (2 C–8 C). Subsequently, MACS
buffer (500 mL) was added to the cell suspension and B cells
were isolated using magnetic separation.
2.2. B cell purity assessment
Purity of B cells was evaluated by ﬂow cytometry using
FITC-conjugated mouse anti-human CD19 (eBiosciences, San
Diego, CA) monoclonal antibody (mAb). Brieﬂy, isolated B
cells were washed twice with washing buffer (PBS 0.15 M,
0.5%BSA, 0.1% NaN3) and incubated with FITC-conjugated
anti CD19 for 40 min at 4 C in the dark place. After incuba-
tion, the cells were washed with washing buffer. Percent of
CD19 positive population was determined using ﬂow cytometer
(BD FACSCalibur). Data were analyzed using the FlowJo
software version 7.2.5 (Tree Star Inc., USA). The purity of B
cells was usually greater than 90% (Figure 1).
2.3. Treatment of puriﬁed B cells with different
concentration of recombinant LPG3, NT-LPG3 and CT-
LPG3 fragments
Puriﬁed B cells were co-incubated with recombinant LPG3,
NT-LPG3 and CT-LPG3 fragments that were produced at Pasteur
institute, Iran [20] and were kindly gifted from Professor Rafati.
Brieﬂy, 1 × 106 B cells were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum (Gibco, USA), peni-
cillin (100 IU) and streptomycin (100 mg/mL) (Biosera, UK) The
cells were treated with different concentrations of recombinant
LPG3, NT andCT fragments (2, 10 and 20 mg/mL) for 24 and 48 h
at 37 C in a humidiﬁed 5% CO2 incubator.
2.4. Cytokine assay
To evaluate the effects of LPG3 and its fragments on the pro-
duction of IL-6, TNF-a and IL-10 by B cells, cell free supernatants
of the cultured cells were harvested and the concentrations of IL-6,
TNF-a and IL-10weremeasured by standard sandwich ELISAkitsody. (A) Unstained cells. (B) B cell enriched fraction.
Figure 2. Expression of CD69 by B cells treated with 10 mg/mL rLPG3
and its fragments for 24–48 h.
LPG3 and NT-LPG3 has the most stimulatory effect on CD69 expression.
Data represents mean ± SD (P value < 0.05).
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Brieﬂy, 96-well microtiter plates were coated with anti-IL-6, anti-
TNF-a and anti-IL-10 coating Abs in 100 mM Na2HPO4, pH 9.0,
incubated for 12 h at 4 C, and blocked with blocking buffer con-
taining 0.05% Tween20 and 10% FBS. Collected supernatants and
recombinant IL-6, TNF-a and IL-10 standards were added (R&D
Systems) and incubated at room temperature for 2 h. Following
washing, biotinylated anti IL-6, TNF-a and IL-10 antibodies were
added and incubated for 60 min at room temperature. Following
washing, microtiter plates were incubated with streptavidine-
polyHRP conjugate with p-nitrophenyl phosphate (4 mg/mL) as
substrate. The absorbance at 405 nm was measured using a mi-
crotiter plate reader and the concentrations of IL-6, TNF-a and IL-
10were calculated froma standard curve of recombinant human IL-
6, TNF-a and IL-10 standards, respectively. The concentrations of
IL-6, TNF-a and IL-10 for each sample was calculated by regres-
sion analysis using the mean absorbance (average of triplicate
readings of the samples added).
2.5. Assessment of B cell activation markers by ﬂow
cytometry
Expressions of CD69 were evaluated by ﬂow cytometry to
demonstrate activation state of B cells treated with rLPG3, CT
and NT fragments. Brieﬂy, 106 cells were washed with PBS and
stained with anti-CD69 PE and anti-CD19 FITC monoclonal
antibodies (eBiosciences, San Diego, CA). Following 45 min
incubation at 4 C in dark, the cells were washed and analyzed
by ﬂow cytometer and by FlowJo software.
2.6. Statistical analysis
For analysis of cytokine production, an intergroup comparison
was performed by Kruskal–Wallis non-parametric ANOVA test.
P-values below 0.05 were regarded as statistically signiﬁcant.Figure 3. Dot plots demonstrating analysis method used for assessment of CD
treated with rLPG3.3. Results
3.1. Recombinant LPG3 and its fragments stimulate the
expression of CD69 on B cells
The representative dot plots illustrating the analysis method
used for assessment of CD69 expressing B cells are shown in
Figure 2. As shown in Figure 3, the stimulation of B cells with
LPG-3 and NT fragment (but not CT fragment) could signiﬁ-
cantly increase the expression of CD69 on B cells (P < 0.05).
3.2. Recombinant LPG3 induced IL-6 production in B
cells
The treatment of B cells with 10 and 20 mg/ml concentrations
of recombinant LPG3 led to signiﬁcant increase in secretion of69 expressing B cells (A) isotype control (B) untreated B cells (C) B cells
Figure 6. IL-10 secretion by B cells treated with rLPG3 and its fragments
for 24–48 h.
LPG3 and its fragments had no stimulatory effect on IL-10 secretion by B
cells.
Figure 5. TNF-a secretion by B cells treated with rLPG3 and its fragments
for 24–48 h.
Secretion of TNF-a in 10 and 20 mg/mL of rLPG3 and 20 mg/mL of NT-
LPG3 and CT-LPG3 was statistically signiﬁcant (P value < 0.05).
Figure 4. IL-6 secretion by B cells treated with different concentrations
(2, 10 and 20 mg/mL) of rLPG3 and its fragments for 24–48 h.
Secretion of IL-6 in 10 and 20 mg/mL of rLPG3 and 20 mg/mL of NT-LPG3
and CT-LPG3 was statistically signiﬁcant (P value < 0.05).
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(but not 2 and 10 mg/mL) concentration of recombinant NT and
CT fragments of LPG3 could signiﬁcantly increase the secretion
of IL-6 by B cells.
3.3. Recombinant LPG3 induced TNF-a production in B
cells
Our results showed that the high concentrations (10 and
20 mg/mL) of recombinant LPG3 could signiﬁcantly increase the
production of TNF-a in B cells. On the other hand, only the
highest concentration (20 mg/mL) of NT and CT fragments had
signiﬁcant stimulatory effects on IL-6 secretion by B cells
(Figure 5).
3.4. Effect of recombinant LPG3 and its fragments on
IL-10 production in B cells
Our results showed that recombinant LPG3 and its fragments
had no effects on the production of IL-10 by B cells (Figure 6).
4. Discussion
Active immunotherapy is the novel promising approach for
eliminating and controlling of Leishmania infection. The pres-
ence of potent adjuvant is essential component of effective
active immunotherapy.
In the present study, we were evaluated the B cell stimulating
potential of different concentrations of LPG3, NT-LPG3 and
CT-LPG3 fragments. CD69 is an important activation marker
that expresses on the surface of mature lymphocytes [21]. We
found that rLPG3 and its NT fragment have a signiﬁcant
effect on upregulation of CD69 on the surface of puriﬁed B
cells.
It has been demonstrated that B cell-derived antibodies
facilitate the phagocytosis of Leishmania major. Moreover, it
observed that the higher parasite burden was associated with a
reduction of T cell response and IFN-g production in mice
lacking antibodies following infection [22]. Furthermore, reduced
chemotaxy of monocytes and lymphocytes at the site of
cutaneous lesion has been observed in B lymphocytes
deﬁcient mice compared to wild type [23]. B cells also produce
several pro-inﬂammatory and anti-inﬂammatory cytokines
which regulate the immune response during Leishmania infec-
tion [24]. Our results indicate that recombinant LPG3 could
activate B lymphocytes to produce and secrete IL-6 and TNF-
a but not IL-10. Moreover, NT and CT fragments are able to
induce IL-6 and TNF-a secretion.
IL-6 as a multifunctional cytokine promotes inﬂammatory
responses against infection. Moreover, IL-6 participates in the
development of Th1 and Th2 immune responses in mammals
[25,26]. However, the function of IL-6 as a pro-inﬂammatory
cytokines in cell-mediated immunity against leishmaniasis has
not been clearly understood [27]. Akuffo et al. [28] demonstrated
that Leishmania aethiopica antigen enhances the production of
IL-6 from PBMCs of localized cutaneous leishmaniasis pa-
tients more than in adults healthy volunteers.
IL-10 is an immune-modulatory cytokine and mediates a
variety of both immunosuppressive and immunostimulatory
activities in mouse and human immune cells [29]. IL-10 is the
one of important anti-inﬂammatory cytokines [30], countered as a
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demonstrated that IL-10 can proceed parasite persistence [23].
Moreover, the immune suppressor activity of IL-10 has been
indicated both in human [33] and mice visceral leishmaniasis [34].
A recent study demonstrated that IL-10-deﬁcient BALB/c mice
are highly resistant to Leishmania donovani infection [34].
However, our results showed that none of the LPG-3 and its
fragments had effects on the production of IL-10 by B cells.
It has been demonstrated that TNF-a has a protective effect
in experimental mouse cutaneous leishmaniasis [35].
Consistently, it is reported that treatment of mice with TNF-a
could decrease parasitic burden and lesion size [36,37].
Our data were consistent with previous report [20] regarding
the immunogenic nature of recombinant LPG3 in BALB/c
mice. Moreover, Larreta et al. [38] reported that 84% of the
dogs visceral leishmaniasis sera reacted with Leishmania
infantum LPG3.
In conclusion, recombinant LPG3 stimulates human B cells
to secrete pro-inﬂammatory IL-6 and TNF-a cytokines and in-
hibits production of regulatory IL-10 cytokine that may be
considered as a promising candidate for Leishmania vaccine
design in near future.
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